The stock price of the pharmaceutical corporation Kips Pharma is rising in early trading on the 8th. This is interpreted as an increase in expectations for new drug development, as the oral platform technology 'Oraloid' related to the 'oral obesity treatment' under development by the company recorded a high bioavailability (oral absorption rate) in large animal experiments.
As of 9:14 a.m. on the same day, Kips Pharma is trading at 19,590 won, up 490 won (2.57%) from the previous trading session. After opening, it soared to 24,800 won, up 29.8%, setting a new annual high.
Kips Pharma noted that after the market closed the previous day, it confirmed a bioavailability of up to 38% in a non-clinical trial of Oraloid targeting Beagle dogs through its subsidiary Kips Biomed.
The company emphasized that with the confirmation of a higher absorption rate in large animal experiments compared to competitors, a green light has been given for the clinical entry and commercialization of the Oraloid technology. Earlier, in non-clinical trials involving rodents, the relative bioavailability of the insulin-loaded Oraloid was recorded at 35%.
A representative from Kips Pharma said, 'As the Oraloid technology possesses versatility for peptide-based obesity treatments, which have recently seen an influx of various candidate substances, we will focus on advancing our platform technology to continue the development of oral obesity treatments.'